DAVID FIGUEROA: Open Payments
NPI 1497107205 · ERIE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$517 in 19 payments from 7 companies in 2025. Trend: 2023 $344 · 2024 $383 · 2025 $517
Food & beverage: $517
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 6 | $239 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
Products named: ARISTADA, LYBALVI, Auvelity, CAPLYTA, Jornay PM, ABILIFY ASIMTUFII, REXULTI, INGREZZA.
Industry payments across PA — which companies pay providers there.
